Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995

Clin Endocrinol (Oxf). 1987 Oct;27(4):469-73. doi: 10.1111/j.1365-2265.1987.tb01175.x.

Abstract

Acute suppression of insulin secretion from pancreatic insulinomas by long-acting somatostatin analogue SMS 201-995 has been documented. We report the chronic use of the drug in a patient with persistent hypoglycaemia due to benign pancreatic microadenomatosis with satisfactory control of plasma glucose level and reduction of insulin production. There was no tachyphylaxis or untoward side-effect noted during the 6-month treatment period.

Publication types

  • Case Reports

MeSH terms

  • Adenoma / complications*
  • Adenoma / metabolism
  • Adenoma / surgery
  • Female
  • Humans
  • Hypoglycemia / drug therapy*
  • Hypoglycemia / etiology
  • Insulin / metabolism
  • Insulin Secretion
  • Middle Aged
  • Octreotide
  • Pancreatectomy
  • Pancreatic Neoplasms / complications*
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / surgery
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use

Substances

  • Insulin
  • Somatostatin
  • Octreotide